Vaccine Typhoid – (1500) at Dr. Essa Lab

Vaccine Typhoid – (1500) at Dr. Essa Lab

The Vaccine Typhoid – (1500) at Dr. Essa Lab is a premier preventive immunization service designed to provide robust active immunity against typhoid fever, a potentially life-threatening systemic infection caused by the bacterium Salmonella enterica serovar Typhi. Typhoid fever remains a significant public health challenge in developing nations, particularly within urban centers like Karachi, Pakistan, where water sanitation and food hygiene infrastructures face ongoing challenges. This specific vaccine service, coded or priced under the designation (1500), represents a highly effective, clinically proven intervention to safeguard children and adults from the debilitating effects of typhoid infection, including the highly concerning Extensively Drug-Resistant (XDR) strains prevalent in the region.

The vaccine works by introducing a tiny, non-infectious component of the Salmonella Typhi bacterium—typically the purified Vi capsular polysaccharide, or in highly advanced formulations, the Vi capsular polysaccharide conjugated to a carrier protein like tetanus toxoid (TCV)—into the body. This exposure stimulates the patient’s immune system, specifically B-lymphocytes, to produce highly specific protective IgG antibodies. Should the patient encounter the actual pathogen in the future through contaminated food or water, these pre-formed antibodies immediately recognize, bind to, and neutralize the bacteria, preventing systemic invasion, bacteremia, and the severe clinical complications associated with typhoid fever. Administering this vaccine at Dr. Essa Lab ensures that patients receive a clinically validated, properly stored, and professionally administered immunizing agent that meets international standards of safety and efficacy.

The diagnostic and preventive value of the Vaccine Typhoid – (1500) cannot be overstated. By choosing Dr. Essa Lab, patients benefit from a state-of-the-art clinical environment where vaccine potency is meticulously preserved through a continuous, monitored cold chain system. The primary benefit of this vaccination is the prevention of severe clinical symptoms such as sustained high fevers, abdominal pain, hepatosplenomegaly, gastrointestinal complications (including intestinal perforation), and encephalopathy. Furthermore, widespread vaccination plays a critical role in community health by establishing herd immunity and reducing the overall reservoir of Salmonella Typhi, thereby limiting the transmission cycle of this waterborne pathogen. Common indications for this vaccine include routine childhood immunization, pre-travel preparation for individuals visiting endemic regions, occupational safety for healthcare and laboratory workers, and preventive care for residents living in high-risk urban and peri-urban communities.

Clinical Procedure: What to Expect

Patient Preparation

To ensure maximum safety and optimal immune response, patients undergoing the Vaccine Typhoid – (1500) at Dr. Essa Lab should adhere to the following preparation guidelines:

• No Fasting Required: Patients do not need to fast before receiving the vaccine. It is highly recommended to eat a light meal and stay well-hydrated prior to the appointment to minimize the risk of vasovagal syncope (fainting) associated with needle apprehension.
• Medical History Disclosure: Inform the healthcare provider of any known allergies, particularly history of severe allergic reactions (anaphylaxis) to any previous vaccine or vaccine component.
• Current Health Status: If the patient is experiencing an acute moderate-to-severe febrile illness (high fever), it is medically advisable to defer the vaccination until the illness has fully resolved. Mild illnesses, such as a common cold or low-grade fever, are generally not contraindications.
• Medication Review: Disclose all current medications, especially immunosuppressive therapies (such as high-dose systemic corticosteroids, chemotherapy, or biological agents) which may reduce the immunogenic efficacy of the vaccine.
• Comfortable Attire: Wear loose-fitting clothing or short sleeves that allow easy access to the deltoid muscle of the upper arm, which is the preferred site for intramuscular or subcutaneous injection in adults and older children.

During the Procedure

The administration of the Vaccine Typhoid – (1500) at Dr. Essa Lab is conducted under strict aseptic conditions by highly trained clinical nurses. The step-by-step process is designed to maximize patient comfort and safety:

• Patient Positioning: The patient is comfortably seated in a vaccination chair. Infants or young children may be held securely by a parent or guardian in a comforting position to prevent sudden movement.
• Site Selection and Asepsis: The clinical staff identifies the injection site—typically the deltoid muscle of the non-dominant upper arm for adults and older children, or the anterolateral aspect of the thigh for infants and toddlers. The skin is thoroughly cleansed with an alcohol swab and allowed to air dry completely.
• Syringe Preparation: The nurse verifies the vaccine vial, checking the expiration date, batch number, and cold chain indicator. The single-dose syringe is prepared using sterile, single-use medical equipment.
• Injection Technique: Using a precise, rapid motion, the nurse administers the vaccine via an intramuscular (IM) or deep subcutaneous injection, depending on the specific vaccine formulation. The patient may feel a brief, mild pinching sensation or localized pressure during the injection, which typically lasts only a few seconds.
• Post-Injection Care: A sterile cotton ball or adhesive bandage is applied to the injection site with gentle pressure. The patient is advised not to rub the area to prevent localized irritation.
• Observation Period: To ensure patient safety, individuals are requested to remain in the waiting area of Dr. Essa Lab for approximately 15 to 20 minutes post-vaccination. This standard clinical precaution allows the medical team to monitor for any immediate, rare allergic reactions or transient dizziness.

When is a Vaccine Typhoid – (1500) Performed?

Prevention of Endemic Typhoid Fever in Pakistan

Typhoid fever is highly endemic throughout Pakistan, with dense urban centers like Karachi experiencing high transmission rates due to compromised municipal water supplies and variable food hygiene standards. Physicians strongly recommend the Vaccine Typhoid – (1500) as a routine preventive measure for all residents, particularly children over the age of two, to build long-term immunity. By administering the vaccine proactively, healthcare providers can dramatically reduce the incidence of typhoid fever, protecting vulnerable populations from the severe morbidity associated with the disease.

Protection Against Extensively Drug-Resistant (XDR) Typhoid

In recent years, the emergence of Extensively Drug-Resistant (XDR) Salmonella Typhi strains in Sindh, Pakistan, has complicated standard medical treatment, as these strains are resistant to almost all first-line and second-line antibiotics. This resistance makes treatment exceptionally difficult, expensive, and increases the risk of severe complications. The Vaccine Typhoid – (1500) is highly recommended by infectious disease specialists as the primary defensive shield against these resistant strains, ensuring that individuals develop robust immunological defenses that bypass the need for complex antibiotic interventions.

Pre-Travel Immunization for International and Domestic Travelers

Travelers visiting Pakistan from non-endemic countries, as well as individuals traveling domestically between different provinces, are at a heightened risk of contracting typhoid fever due to lack of prior exposure and natural immunity. Travel medicine clinics frequently prescribe the Vaccine Typhoid – (1500) at least two weeks prior to travel. This timeline is crucial, as it allows the patient’s immune system sufficient time to undergo seroconversion and produce protective levels of neutralizing IgG antibodies before potential exposure.

Occupational Safety for Healthcare and Laboratory Personnel

Clinical laboratory technicians, microbiologists, and healthcare professionals working in diagnostic centers like Dr. Essa Lab are routinely exposed to clinical specimens containing active Salmonella Typhi. Accidental inoculation or exposure represents a significant occupational hazard. For these professionals, receiving the Vaccine Typhoid – (1500) is an essential occupational health protocol, providing a vital layer of biological protection that minimizes the risk of laboratory-acquired infections.

Community and Household Contact Protection

When a household member is diagnosed with typhoid fever or identified as a chronic asymptomatic biliary carrier of Salmonella Typhi, the risk of transmission to other family members through shared food, water, and close contact is exceptionally high. In such scenarios, physicians recommend immediate vaccination of all close contacts using the Vaccine Typhoid – (1500). This targeted immunization strategy helps contain the localized spread of the pathogen, protecting the immediate family and the broader community from secondary outbreaks.

What Does a Vaccine Typhoid – (1500) Prevent and Evaluate?

The Vaccine Typhoid – (1500) is a preventive immunological intervention. While it is not a diagnostic test that detects an active disease, its clinical administration involves evaluating several physiological and immunological parameters to ensure safety, efficacy, and successful immunization. The clinical parameters, protective outcomes, and safety evaluations associated with this vaccine include:

• Prevention of Salmonella Typhi Bacteremia: Prevents the entry and multiplication of typhoid bacilli in the bloodstream.
• Reduction of Intestinal Perforation Risk: Protects against severe ulceration of Peyer’s patches in the terminal ileum, a classic complication of advanced typhoid.
• Prevention of Sustained High Pyrexia: Eliminates the risk of developing the characteristic “step-ladder” high fever associated with typhoid.
• Mitigation of Hepatosplenomegaly: Prevents inflammatory enlargement of the liver and spleen caused by systemic intracellular bacterial replication.
• Protection Against Typhoid Encephalopathy: Guards against severe neuropsychiatric symptoms, delirium, and confusion caused by systemic endotoxemia.
• Stimulation of Vi-Specific IgG Antibodies: Evaluates the body’s capability to undergo successful seroconversion and maintain protective antibody titers.
• Prevention of Chronic Biliary Carrier State: Prevents the colonization of the gallbladder, which can turn individuals into long-term asymptomatic shedders of the bacteria.
• Reduction of Antibiotic Dependency: Lowers the societal and individual need for broad-spectrum antibiotics, directly combating the global threat of antimicrobial resistance.
• Assessment of Local Reactogenicity: Monitoring for mild, expected local physiological responses such as transient erythema, mild induration, and localized tenderness at the injection site.
• Assessment of Systemic Reactogenicity: Monitoring for minor systemic responses such as low-grade transient fever, mild headache, or myalgia, which indicate active immune system stimulation.
• Screening for Immediate Hypersensitivity: Clinical surveillance for rare immediate IgE-mediated allergic reactions, including urticaria, bronchospasm, or anaphylaxis.
• Evaluation of Contraindications: Comprehensive pre-vaccine assessment of patient history for immunodeficiency states, immunosuppressive therapies, or past vaccine hypersensitivity.
• Verification of Cold Chain Integrity: Ensuring the vaccine was stored between 2°C and 8°C, preserving the structural integrity of the Vi antigen.
• Efficacy Against Multidrug-Resistant (MDR) Strains: Provides proven immunological protection against strains resistant to chloramphenicol, ampicillin, and co-trimoxazole.
• Efficacy Against Extensively Drug-Resistant (XDR) Strains: Confers vital protection against strains resistant to third-generation cephalosporins and fluoroquinolones.
• Long-Term Immunological Memory: Stimulates memory B-cells to provide prolonged protection, reducing the frequency of required booster doses.
• Reduction of Gastrointestinal Morbidity: Prevents severe diarrhea, constipation, abdominal tenderness, and bloating associated with localized intestinal inflammation.
• Prevention of Typhoid Myocarditis: Guards against toxic myocarditis, a rare but severe cardiovascular complication of systemic typhoid infection.
• Prevention of Focal Metastatic Infections: Prevents the bacteria from seeding into bones, joints, meninges, or lungs, avoiding osteomyelitis, arthritis, meningitis, or empyema.
• Public Health Protection: Contributes to the reduction of the overall reproductive rate (R0) of the pathogen within the community.

Turnaround Time and Report Access at Dr. Essa Lab

Upon receiving the Vaccine Typhoid – (1500) at Dr. Essa Lab, the patient’s immunization record is immediately updated. A physical vaccination card, detailing the vaccine brand, batch number, manufacturing date, expiration date, and date of administration, is filled out and handed to the patient before they leave the facility. This card serves as an official medical document for school admissions, international travel, and occupational health records.

In addition to the physical card, Dr. Essa Lab utilizes a highly advanced, fully integrated Laboratory Information Management System (LIMS). The details of the vaccination, including the administering nurse’s credentials and the specific vaccine lot, are digitally logged into the patient’s electronic health record. Patients can access their digital vaccination certificates and complete medical history online through the official Dr. Essa Lab web portal or mobile application. This digital access ensures that patients can retrieve their immunization records securely at any time, from anywhere in the world, providing unmatched convenience and peace of mind.

Vaccine Typhoid – (1500) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Injection Site Condition	No reaction, or mild transient redness and slight tenderness resolving within 24–48 hours.	Severe localized pain, extensive swelling, persistent induration, or abscess formation (rare).
Systemic Temperature	Apyrexial (normal body temperature) or mild, transient low-grade fever (< 38°C) for 12–24 hours.	High-grade fever (> 38.5°C), prolonged pyrexia, or rigors requiring medical evaluation.
Immunological Response (IgG)	Successful seroconversion with protective levels of anti-Vi IgG antibodies within 2–4 weeks.	Failure to seroconvert (blunted immune response), occasionally seen in severely immunocompromised patients.
Allergic / Hypersensitivity Reaction	Absence of immediate or delayed allergic symptoms; normal respiratory and dermatological status.	Immediate urticaria, angioedema, bronchospasm, or anaphylaxis (extremely rare; requires emergency intervention).
Gastrointestinal Status	Normal appetite, absence of nausea, vomiting, abdominal pain, or diarrhea.	Persistent nausea, vomiting, or severe abdominal cramping post-administration.
Neurological Status	No neurological symptoms, or mild transient headache resolving with simple analgesics.	Severe, unrelenting headache, extreme lethargy, or paresthesia (requires clinical review).
Vaccine Vial & Cold Chain Status	Vaccine maintained continuously between 2°C and 8°C; vial monitor intact and within safety limits.	Exposure to freezing or excessive heat, compromised vial integrity, or expired vaccine lot.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Vaccine Typhoid – (1500)?

• Experienced Healthcare Professionals: Our clinical team consists of highly trained, compassionate nurses and pathologists dedicated to providing safe and accurate immunization services.
• Strict Cold Chain Maintenance: Dr. Essa Lab utilizes state-of-the-art refrigeration and continuous temperature monitoring systems to ensure that vaccines retain 100% of their potency and efficacy.
• ISO Certified Quality Standards: Operating under rigorous quality control protocols, Dr. Essa Lab maintains international standards of clinical excellence and patient safety.
• Extensive Branch Network: With numerous conveniently located collection centers across Karachi and other major cities, accessing quality healthcare services is always convenient.
• Advanced Digital Portal: Patients can easily access, download, and share their digital vaccination records and diagnostic reports through our secure online portal.
• Patient-Focused Care: We prioritize patient comfort, offering a welcoming, clean, and stress-free environment for both pediatric and adult patients.
• Home Vaccination Services: For added convenience, Dr. Essa Lab offers professional home health services, allowing patients to receive vaccinations in the comfort of their homes.
• Legacy of Trust: Serving the community since 1987, Dr. Essa Lab is one of Pakistan’s most trusted diagnostic and preventive healthcare institutions, recognized for accuracy and reliability.